Shandong Sito Bio-technology Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shandong Saituo Biotechnology Co., Ltd. was founded in 2010 and focuses on the research and production of steroid drug intermediates. In 2017, it was successfully listed on the Shenzhen Stock Exchange and covers an area of over 940 acres. The company is based in the cutting-edge field of biopharmaceuticals and, after years of independent research and development and technology introduction, has taken the lead in achieving the large-scale application of biopharmaceutical technology in the field of steroidal drugs. It is a biopharmaceutical high-tech enterprise that applies genetic engineering technology and microbial transformation technology, specializing in the research and production of new steroidal raw materials drugs. The company adheres to the path of technological innovation and maintains long-term and good cooperative relationships with multiple well-known high-end research institutions in China; Established a key engineering laboratory in Shandong Province; From basic research to applied research, a complete series of steroid product production lines have been established in China through various methods such as independent research and development, cooperation with research institutions, and hiring domestic and foreign industry experts; A total of 30 intellectual property applications have been made, of which 19 have been authorized, and the average annual R&D projects remain at least 5. The company adheres to the use of an international standard management system to promote its various management work, and has successively passed certifications such as the ISO90001 quality management system, ISO14000 environmental management system, ISO18000 safety and health management system, and ISO50001 energy management system. Up to now, the company has completed the entire industrial chain layout from basic raw materials of steroid drugs to terminal formulations. In the future, the company will continue to uphold the values of honesty and trustworthiness, pragmatic innovation, and harmonious win-win, and build a biotechnology enterprise that integrates pharmaceutical intermediates, raw materials, and finished products. |
| Headquarter | Heze City |
| Establish Date | 1/19/2010 |
| Listed Code | 300583.SZ |
| Listed Date | 1/6/2017 |
| Chairman | Mickey. |
| CEO | Jin Lianbiao. |
| Website | www.sitobiotech.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
